AstraZeneca Puts $2 Billion Into Summit, Whose Drug Beat AstraZeneca’s Own Imfinzi in Biliary Cancer
- Summit Therapeutics said on 28 September 2026 that AstraZeneca will invest $2.0bn in convertible preferred stock, equal to $18.36 a common share, the prior week’s five-day volume-weighted average price plus 10%. Closing is expected this week.
- The companies will test ivonescimab, Summit’s PD-1/VEGF bispecific, with AstraZeneca’s Claudin 18.2 antibody-drug conjugate sonesitatug vedotin in gastrointestinal cancers, sponsored by AstraZeneca and cost-shared. A non-binding memorandum covers combinations with other AstraZeneca ADCs. It is non-exclusive, with no milestones, royalties or profit sharing.
- Summit licenses ivonescimab from Akeso for North and South America, Europe, the Middle East, Africa and Japan. The FDA’s decision on its first US application, in EGFR-mutated lung cancer after targeted therapy, is due on 14 November 2026.
- At ESMO in October, sone-ve’s gastric cancer survival data will be presented alongside Akeso’s HARMONi-GI1, in which ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in first-line biliary tract cancer. Durvalumab is AstraZeneca’s Imfinzi.
Deal read
AstraZeneca bought access, not rights, and paid a premium for it.
- No licence, no royalties, a 10% premium. The $2bn buys equity and a combination partner for AstraZeneca’s ADCs, not the molecule. Summit’s own risk language lists AstraZeneca’s contractual rights, including participation in any third-party acquisition, without giving detail. The deal gives AstraZeneca a seat at the table without the obligations of a licence.
- The drug just beat Imfinzi. HARMONi-GI1 showed ivonescimab plus chemotherapy outperforming durvalumab plus chemotherapy on survival in first-line biliary cancer. An equity stake in the molecule that displaced its own PD-L1 drug in a trial is a hedge as much as a partnership.
- It fits the ADC-as-backbone strategy. AstraZeneca’s oncology head, Susan Galbraith, said PD-1/VEGF bispecifics could improve on current immunotherapies in lung, breast and gastrointestinal cancers. The collaboration lets AstraZeneca test that thesis with its ADCs before the 14 November FDA decision shows whether ivonescimab can reach the US market.